explore -WSS

explore

author：explore 2025-09-30 08:52:59 - browse：83654

Photo illustration of Fyodor Urnov surrounded by DNA strands. -- health coverage from STAT — Christine Kao/STAT

Researchers attending gene therapy meetings over the past couple years were liable to bump into a svelte, graying scientist explaining in emphatic, Russian-inflected English that the U.S. was wasting the grand potential of CRISPR gene editing.

Fyodor Urnov, the scientist in question, estimates he gave the talk 30 to 40 times: to fellow researchers, pharma executives, Food and Drug Administration officials, congressional staff, journalists, patient advocates. “Anyone who would listen,” he says.

The problem was one of scale. Sure, for-profit companies were developing cures for a small handful of genetic diseases, such as sickle cell disease. But there were hundreds of devastating conditions that CRISPR might be able to cure but that no entity was seriously working on.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： UnitedHealth sued over use of algorithm in Medicare Advantage plans

WSS

Lifetime voting ban for felony convictions struck down in Mississippi

Type 2 diabetes prevention programs work at large scale: study

US Marines prepare to be put on commercial ships to deter Iranian harassment in Strait of Hormuz

Medical schools are missing the mark on artificial intelligence

Readout Newsletter: Zepbound, Valneva's vaccine, and more

US Marines prepare to be put on commercial ships to deter Iranian harassment in Strait of Hormuz

hotspot

explore

explore

After affirmative action ruling, medical educators look to 'holistic review'

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Ventyx halts psoriasis drug development after lackluster trial results

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Carbon Health diabetes program, a test of data

Medicare details structure of new drug price negotiation program

Climate activists disrupt London Pride march to protest corporate sponsorship

In Memoriam: Notable people who died in 2023

Slain Parkland victim's father speaks out following reenactment

knowledge

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

New company forms to vet health AI models, root out weaknesses

Pope greeted like rockstar, appears revitalized at 'Catholic Woodstock' in Portugal

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Medical schools are missing the mark on artificial intelligence

explore

focus

hotspot

hotspot